Detection of ROS1 rearrangement in lung cancer remains “complex”

“No testing methodology demonstrated 100% sensitivity in the detection of ROS1 rearrangements or fusions among patients with non-small cell lung cancer, according to study results.”

“The main point is just to be aware of the deficiencies in these assays and not to always trust a negative result from a single test,” Kurtis D. Davies, PhD, lead assay development scientist at Colorado Molecular Correlates Laboratory and instructor at University of Colorado Anschutz Medical Campus, said in a press release. “If you’re suspicious that a patient could be ROS1 positive — maybe they’re a never-smoker without other known drivers such as EGFR, ALK, KRAS, BRAF — then it may be useful to try another kind of test.”

Read the full article here.

Published by

lysa71

mom, wife, daughter, advocate, and stage IV lung cancer survivor.